Fosinopril

Pharmacokinetics and pharmacodynamics in Chinese subjects

Philip Y.A. Ding, Kai Ming Chu, Oliver Yoa Pu Hu, Giang Ming Huang, Jing Jen Jeng, Audrey Chang, Carol L. Delaney, Maynard MacAskill, B. C. Yang, Mohammed Jemal, Robert Smith, Wei Chi Liao

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This study examined the pharmacokinetics and pharmacodynamics of fosinopril (IV and oral) in Chinese subjects to determine whether they were different from a group of somewhat heavier and older Western control subjects previously published using the same methods. It was an open-label, randomized, balanced, two-way crossover study comparing oral and IV pharmacokinetics in 12 healthy Chinese subjects in a clinic in Taiwan. Each subject received 10 mg of oral fosinopril or 7.5 mg of IV fosinoprilat in a randomized sequence with sampling for fosinoprilat concentrations over 48 hours. Standard pharmacokinetics, including AUC, C(max), T(max), T( 1/2 ), V(ss), bioavailability, total clearance, and renal and nonrenal clearance, were determined as well as pharmacodynamic effects on angiotensin-converting enzyme (ACE) activity. Following oral administration of 10 mg fosinopril, AUC(0-T) and AUC(inf) were 1556 ± 586 ng · hr/mL and 1636 ± 620 ng · hr/mL, respectively; T( 1/2 ) was 17.4 ± 11.4 hr; C(max) was 183.4 ± 59.4 ng/mL; and median T(max) was 4.0 hr, with ≥ 99% protein binding. Following IV administration of 7.5 mg fosinoprilat, AUC(0-T) and AUC(inf) were 7727 ± 2638 ng · hr/mL and 7816 ± 2693 ng · hr/mL, respectively; T( 1/2 0) was 13.0 ± 5.2 hr; and median T(max) was 4.0 hr, with 99.5% ± 0.22% protein binding and a V(ss) of 5850 ± 2780 mL. Bioavailability was 22.3% ± 7.9%. Percent urinary excretion was 7.6% ± 2.6% after oral dosing and 42.6% ± 6.1% after IV dosing. After IV, dosing total clearance was 1088 ± 439 mL/hr, renal clearance was 472 ± 213 mL/hr, and nonrenal clearance was 617 ± 246 mL/hr. ACE inhibition was essentially complete through 12 hours and markedly reduced through 24 hours. Compared to a somewhat heavier and older previously reported control group, pharmacokinetic values were similar except for a slightly lower AUC and total clearance in Chinese and a statistically significantly lower nonrenal clearance. Pharmacodynamic effects on ACE activity were essentially identical. There is no reason to expect significant differences in fosinopril dosing or effect in a Chinese population compared to a Western population.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalJournal of Clinical Pharmacology
Volume39
Issue number2
DOIs
Publication statusPublished - Feb 13 1999
Externally publishedYes

Fingerprint

Fosinopril
Area Under Curve
Pharmacokinetics
Peptidyl-Dipeptidase A
Protein Binding
Biological Availability
Kidney
Taiwan
Cross-Over Studies
Population
Oral Administration
Healthy Volunteers
Control Groups

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ding, P. Y. A., Chu, K. M., Hu, O. Y. P., Huang, G. M., Jeng, J. J., Chang, A., ... Liao, W. C. (1999). Fosinopril: Pharmacokinetics and pharmacodynamics in Chinese subjects. Journal of Clinical Pharmacology, 39(2), 155-160. https://doi.org/10.1177/00912709922007705

Fosinopril : Pharmacokinetics and pharmacodynamics in Chinese subjects. / Ding, Philip Y.A.; Chu, Kai Ming; Hu, Oliver Yoa Pu; Huang, Giang Ming; Jeng, Jing Jen; Chang, Audrey; Delaney, Carol L.; MacAskill, Maynard; Yang, B. C.; Jemal, Mohammed; Smith, Robert; Liao, Wei Chi.

In: Journal of Clinical Pharmacology, Vol. 39, No. 2, 13.02.1999, p. 155-160.

Research output: Contribution to journalArticle

Ding, PYA, Chu, KM, Hu, OYP, Huang, GM, Jeng, JJ, Chang, A, Delaney, CL, MacAskill, M, Yang, BC, Jemal, M, Smith, R & Liao, WC 1999, 'Fosinopril: Pharmacokinetics and pharmacodynamics in Chinese subjects', Journal of Clinical Pharmacology, vol. 39, no. 2, pp. 155-160. https://doi.org/10.1177/00912709922007705
Ding, Philip Y.A. ; Chu, Kai Ming ; Hu, Oliver Yoa Pu ; Huang, Giang Ming ; Jeng, Jing Jen ; Chang, Audrey ; Delaney, Carol L. ; MacAskill, Maynard ; Yang, B. C. ; Jemal, Mohammed ; Smith, Robert ; Liao, Wei Chi. / Fosinopril : Pharmacokinetics and pharmacodynamics in Chinese subjects. In: Journal of Clinical Pharmacology. 1999 ; Vol. 39, No. 2. pp. 155-160.
@article{2ffe1ef39a424d70b8da22ca8d88f3a4,
title = "Fosinopril: Pharmacokinetics and pharmacodynamics in Chinese subjects",
abstract = "This study examined the pharmacokinetics and pharmacodynamics of fosinopril (IV and oral) in Chinese subjects to determine whether they were different from a group of somewhat heavier and older Western control subjects previously published using the same methods. It was an open-label, randomized, balanced, two-way crossover study comparing oral and IV pharmacokinetics in 12 healthy Chinese subjects in a clinic in Taiwan. Each subject received 10 mg of oral fosinopril or 7.5 mg of IV fosinoprilat in a randomized sequence with sampling for fosinoprilat concentrations over 48 hours. Standard pharmacokinetics, including AUC, C(max), T(max), T( 1/2 ), V(ss), bioavailability, total clearance, and renal and nonrenal clearance, were determined as well as pharmacodynamic effects on angiotensin-converting enzyme (ACE) activity. Following oral administration of 10 mg fosinopril, AUC(0-T) and AUC(inf) were 1556 ± 586 ng · hr/mL and 1636 ± 620 ng · hr/mL, respectively; T( 1/2 ) was 17.4 ± 11.4 hr; C(max) was 183.4 ± 59.4 ng/mL; and median T(max) was 4.0 hr, with ≥ 99{\%} protein binding. Following IV administration of 7.5 mg fosinoprilat, AUC(0-T) and AUC(inf) were 7727 ± 2638 ng · hr/mL and 7816 ± 2693 ng · hr/mL, respectively; T( 1/2 0) was 13.0 ± 5.2 hr; and median T(max) was 4.0 hr, with 99.5{\%} ± 0.22{\%} protein binding and a V(ss) of 5850 ± 2780 mL. Bioavailability was 22.3{\%} ± 7.9{\%}. Percent urinary excretion was 7.6{\%} ± 2.6{\%} after oral dosing and 42.6{\%} ± 6.1{\%} after IV dosing. After IV, dosing total clearance was 1088 ± 439 mL/hr, renal clearance was 472 ± 213 mL/hr, and nonrenal clearance was 617 ± 246 mL/hr. ACE inhibition was essentially complete through 12 hours and markedly reduced through 24 hours. Compared to a somewhat heavier and older previously reported control group, pharmacokinetic values were similar except for a slightly lower AUC and total clearance in Chinese and a statistically significantly lower nonrenal clearance. Pharmacodynamic effects on ACE activity were essentially identical. There is no reason to expect significant differences in fosinopril dosing or effect in a Chinese population compared to a Western population.",
author = "Ding, {Philip Y.A.} and Chu, {Kai Ming} and Hu, {Oliver Yoa Pu} and Huang, {Giang Ming} and Jeng, {Jing Jen} and Audrey Chang and Delaney, {Carol L.} and Maynard MacAskill and Yang, {B. C.} and Mohammed Jemal and Robert Smith and Liao, {Wei Chi}",
year = "1999",
month = "2",
day = "13",
doi = "10.1177/00912709922007705",
language = "English",
volume = "39",
pages = "155--160",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Fosinopril

T2 - Pharmacokinetics and pharmacodynamics in Chinese subjects

AU - Ding, Philip Y.A.

AU - Chu, Kai Ming

AU - Hu, Oliver Yoa Pu

AU - Huang, Giang Ming

AU - Jeng, Jing Jen

AU - Chang, Audrey

AU - Delaney, Carol L.

AU - MacAskill, Maynard

AU - Yang, B. C.

AU - Jemal, Mohammed

AU - Smith, Robert

AU - Liao, Wei Chi

PY - 1999/2/13

Y1 - 1999/2/13

N2 - This study examined the pharmacokinetics and pharmacodynamics of fosinopril (IV and oral) in Chinese subjects to determine whether they were different from a group of somewhat heavier and older Western control subjects previously published using the same methods. It was an open-label, randomized, balanced, two-way crossover study comparing oral and IV pharmacokinetics in 12 healthy Chinese subjects in a clinic in Taiwan. Each subject received 10 mg of oral fosinopril or 7.5 mg of IV fosinoprilat in a randomized sequence with sampling for fosinoprilat concentrations over 48 hours. Standard pharmacokinetics, including AUC, C(max), T(max), T( 1/2 ), V(ss), bioavailability, total clearance, and renal and nonrenal clearance, were determined as well as pharmacodynamic effects on angiotensin-converting enzyme (ACE) activity. Following oral administration of 10 mg fosinopril, AUC(0-T) and AUC(inf) were 1556 ± 586 ng · hr/mL and 1636 ± 620 ng · hr/mL, respectively; T( 1/2 ) was 17.4 ± 11.4 hr; C(max) was 183.4 ± 59.4 ng/mL; and median T(max) was 4.0 hr, with ≥ 99% protein binding. Following IV administration of 7.5 mg fosinoprilat, AUC(0-T) and AUC(inf) were 7727 ± 2638 ng · hr/mL and 7816 ± 2693 ng · hr/mL, respectively; T( 1/2 0) was 13.0 ± 5.2 hr; and median T(max) was 4.0 hr, with 99.5% ± 0.22% protein binding and a V(ss) of 5850 ± 2780 mL. Bioavailability was 22.3% ± 7.9%. Percent urinary excretion was 7.6% ± 2.6% after oral dosing and 42.6% ± 6.1% after IV dosing. After IV, dosing total clearance was 1088 ± 439 mL/hr, renal clearance was 472 ± 213 mL/hr, and nonrenal clearance was 617 ± 246 mL/hr. ACE inhibition was essentially complete through 12 hours and markedly reduced through 24 hours. Compared to a somewhat heavier and older previously reported control group, pharmacokinetic values were similar except for a slightly lower AUC and total clearance in Chinese and a statistically significantly lower nonrenal clearance. Pharmacodynamic effects on ACE activity were essentially identical. There is no reason to expect significant differences in fosinopril dosing or effect in a Chinese population compared to a Western population.

AB - This study examined the pharmacokinetics and pharmacodynamics of fosinopril (IV and oral) in Chinese subjects to determine whether they were different from a group of somewhat heavier and older Western control subjects previously published using the same methods. It was an open-label, randomized, balanced, two-way crossover study comparing oral and IV pharmacokinetics in 12 healthy Chinese subjects in a clinic in Taiwan. Each subject received 10 mg of oral fosinopril or 7.5 mg of IV fosinoprilat in a randomized sequence with sampling for fosinoprilat concentrations over 48 hours. Standard pharmacokinetics, including AUC, C(max), T(max), T( 1/2 ), V(ss), bioavailability, total clearance, and renal and nonrenal clearance, were determined as well as pharmacodynamic effects on angiotensin-converting enzyme (ACE) activity. Following oral administration of 10 mg fosinopril, AUC(0-T) and AUC(inf) were 1556 ± 586 ng · hr/mL and 1636 ± 620 ng · hr/mL, respectively; T( 1/2 ) was 17.4 ± 11.4 hr; C(max) was 183.4 ± 59.4 ng/mL; and median T(max) was 4.0 hr, with ≥ 99% protein binding. Following IV administration of 7.5 mg fosinoprilat, AUC(0-T) and AUC(inf) were 7727 ± 2638 ng · hr/mL and 7816 ± 2693 ng · hr/mL, respectively; T( 1/2 0) was 13.0 ± 5.2 hr; and median T(max) was 4.0 hr, with 99.5% ± 0.22% protein binding and a V(ss) of 5850 ± 2780 mL. Bioavailability was 22.3% ± 7.9%. Percent urinary excretion was 7.6% ± 2.6% after oral dosing and 42.6% ± 6.1% after IV dosing. After IV, dosing total clearance was 1088 ± 439 mL/hr, renal clearance was 472 ± 213 mL/hr, and nonrenal clearance was 617 ± 246 mL/hr. ACE inhibition was essentially complete through 12 hours and markedly reduced through 24 hours. Compared to a somewhat heavier and older previously reported control group, pharmacokinetic values were similar except for a slightly lower AUC and total clearance in Chinese and a statistically significantly lower nonrenal clearance. Pharmacodynamic effects on ACE activity were essentially identical. There is no reason to expect significant differences in fosinopril dosing or effect in a Chinese population compared to a Western population.

UR - http://www.scopus.com/inward/record.url?scp=0032950729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032950729&partnerID=8YFLogxK

U2 - 10.1177/00912709922007705

DO - 10.1177/00912709922007705

M3 - Article

VL - 39

SP - 155

EP - 160

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 2

ER -